carnitine has been researched along with Hypertension in 51 studies
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mean level of serum L-carnitine in the stroke population was 4." | 8.12 | Serum L-Carnitine Levels Are Associated With First Stroke in Chinese Adults With Hypertension. ( Duan, Y; Guo, H; Huo, Y; Li, J; Liu, L; Liu, X; Qin, X; Song, Y; Wang, B; Wang, X; Xu, X; Zhang, H; Zhang, N; Zhang, Y; Zhou, Z, 2022) |
| " Sitagliptin and clonidine are effective curing drugs for controlling diabetes and hypertension, while insulin and norepinephrine are the biomarkers of these two diseases." | 8.12 | Chiral Luminescent Sensor Eu-BTB@d-Carnitine Applied in the Highly Effective Ratiometric Sensing of Curing Drugs and Biomarkers for Diabetes and Hypertension. ( Ding, B; Huo, J; Jiang, YP; Liu, YY; Shi, YF; Sun, PP; Wang, K; Wang, XR; Wang, XZ; Zhang, ZQ; Zhu, NJ, 2022) |
| "In symptomatic patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, circulating levels of long-chain acylcarnitines were independently associated with measures of maladaptive LV remodeling, and metabolic perturbations lessened after procedure completion." | 7.88 | Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. ( Elmariah, S; Farrell, LA; Furman, D; Gerszten, RE; Lindman, BR; Morningstar, JE; Rhee, EP; Shi, X, 2018) |
| "The article investigates the impact of complex tools fosinopril, hepadyf and ezetimibe for correction of functional state of the endothelium and changes in blood pressure in patients with nonalcoholic steatohepatitis, obesity and essential hypertension stage II." | 7.80 | [The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II]. ( Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe, 2014) |
| "This study confirms the efficacy of L-carnitine against hypertension-associated renal fibrosis from in vivo and in vitro studies and suggests that the L-carnitine effect occurs in a PPAR-γ-dependent manner." | 7.80 | L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014) |
| "These results identify the carnitine-transporter gene family as candidate modifiers of LVMI in human hypertension." | 7.73 | Haplotype analysis of carnitine transporters and left ventricular mass in human essential hypertension. ( Bianchi, G; Bigatti, G; Modica, R; Stella, A; Stella, P; Tripodi, G, 2005) |
| "This study was undertaken to demonstrate L-carnitine therapeutical effect in patients with essential hypertension." | 7.69 | L-carnitine adjuvant therapy in essential hypertension. ( Bisi, G; Brodbeck, B; Cantini, F; Digiesi, V; Guarino, G, 1994) |
| "Reduced myocardial carnitine concentrations in the explanted heart and elevated plasma levels have been found in patients undergoing heart transplant for end-stage congestive heart failure (CHF)." | 7.68 | Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. ( Fleck, E; Regitz, V; Shug, AL, 1990) |
| "Carnitine is a natural substance essential for the mitochondrial oxidation of long-chain fatty acids and therefore regulates the energy metabolism of the cells." | 6.66 | [The benefits of L-carnitine therapy in essential arterial hypertension with diabetes mellitus type II]. ( Cantini, F; Digiesi, V; Palchetti, R, 1989) |
| "l-carnitine (LC) is a naturally occurring compound that is administered exogenously for treatment of patients that are deficient in carnitine." | 6.46 | The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage. ( Mate, A; Miguel-Carrasco, JL; Vázquez, CM, 2010) |
| "Cardiac fibrosis is a pathogenic factor in a variety of cardiovascular diseases and is characterized by an abnormal accumulation of extracellular matrix protein that leads to cardiac dysfunction." | 5.39 | L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Vázquez, MJ; Zambrano, S, 2013) |
| "Treatment with captopril was also performed in SHR in order to compare the antioxidant and antihypertensive effects of LC and captopril." | 5.36 | Systemic antioxidant properties of L-carnitine in two different models of arterial hypertension. ( Mate, A; Miguel-Carrasco, JL; Monserrat, MT; Vázquez, CM, 2010) |
| "The chronic administration of LC reduces blood pressure and attenuates the inflammatory process associated with arterial hypertension." | 5.35 | The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. ( Aramburu, O; Arias, JL; Mate, A; Miguel-Carrasco, JL; Monserrat, MT; Vázquez, CM, 2008) |
| " Sitagliptin and clonidine are effective curing drugs for controlling diabetes and hypertension, while insulin and norepinephrine are the biomarkers of these two diseases." | 4.12 | Chiral Luminescent Sensor Eu-BTB@d-Carnitine Applied in the Highly Effective Ratiometric Sensing of Curing Drugs and Biomarkers for Diabetes and Hypertension. ( Ding, B; Huo, J; Jiang, YP; Liu, YY; Shi, YF; Sun, PP; Wang, K; Wang, XR; Wang, XZ; Zhang, ZQ; Zhu, NJ, 2022) |
| "The mean level of serum L-carnitine in the stroke population was 4." | 4.12 | Serum L-Carnitine Levels Are Associated With First Stroke in Chinese Adults With Hypertension. ( Duan, Y; Guo, H; Huo, Y; Li, J; Liu, L; Liu, X; Qin, X; Song, Y; Wang, B; Wang, X; Xu, X; Zhang, H; Zhang, N; Zhang, Y; Zhou, Z, 2022) |
| "In symptomatic patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, circulating levels of long-chain acylcarnitines were independently associated with measures of maladaptive LV remodeling, and metabolic perturbations lessened after procedure completion." | 3.88 | Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. ( Elmariah, S; Farrell, LA; Furman, D; Gerszten, RE; Lindman, BR; Morningstar, JE; Rhee, EP; Shi, X, 2018) |
| "l-Carnitine (LC) exerts beneficial effects in arterial hypertension due, in part, to its antioxidant capacity." | 3.85 | l-Carnitine ameliorates the oxidative stress response to angiotensin II by modulating NADPH oxidase through a reduction in protein kinase c activity and NF-κB translocation to the nucleus. ( Blanca, AJ; Fortuño, A; González-Roncero, FM; Mate, A; Miguel-Carrasco, JL; Revilla, E; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2017) |
| "This study was performed to test the hypothesis that urinary levels of L-carnitine and its derivatives are enhanced in children and adolescents with hypertension and also check if analyzed parameters may serve as early markers of subclinical renal damage." | 3.81 | Urine L-carnitine excretion in hypertensive adolescents. ( Chojnowska, S; Fiłonowicz, R; Kępka, A; Korzeniecka-Kozerska, A; Kuroczycka-Saniutycz, E; Wasilewska, A, 2015) |
| "The article investigates the impact of complex tools fosinopril, hepadyf and ezetimibe for correction of functional state of the endothelium and changes in blood pressure in patients with nonalcoholic steatohepatitis, obesity and essential hypertension stage II." | 3.80 | [The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II]. ( Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe, 2014) |
| "This study confirms the efficacy of L-carnitine against hypertension-associated renal fibrosis from in vivo and in vitro studies and suggests that the L-carnitine effect occurs in a PPAR-γ-dependent manner." | 3.80 | L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014) |
| " Serum markers of endothelial dysfunction and inflammation were unchanged, but short-chain acylcarnitine concentrations were significantly decreased." | 3.79 | Daily non-soy legume consumption reverses vascular impairment due to peripheral artery disease. ( Baldwin, A; Blewett, H; Guzman, RP; O, K; Taylor, CG; Weighell, W; Wright, B; Zahradka, P, 2013) |
| ") and 1% NaCl in drinking water for 28 days developed cardiovascular remodelling shown as systolic hypertension, left ventricular hypertrophy, increased thoracic aortic and left ventricular wall thickness, increased left ventricular inflammatory cell infiltration together with increased interstitial collagen and increased passive diastolic stiffness and vascular dysfunction with increased plasma malondialdehyde concentrations." | 3.76 | L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats. ( Brown, L; Chunduri, P; Iyer, A; O'Brien, D, 2010) |
| "The present study aimed to investigate whether l-carnitine (LC) protects the vascular endothelium and tissues against oxidative damage in hypertension." | 3.74 | L-carnitine attenuates oxidative stress in hypertensive rats. ( Cameán, AM; Gómez-Amores, L; Jiménez, L; Jos, A; Mate, A; Miguel-Carrasco, JL; Revilla, E; Santa-María, C; Vázquez, CM, 2007) |
| " At 4 weeks after ascending aortic constriction, jvs/+ mice showed an exaggeration of cardiac hypertrophy and pulmonary congestion, further increased gene expression of atrial natriuretic peptide in the left ventricles, further deterioration of left ventricular fractional shortening, reduced myocardial phosphocreatine:adenosine triphosphate ratio, and increased mortality compared with wild-type mice; l-carnitine supplementation prevented these changes in jvs/+ mice subjected to ascending aortic constriction." | 3.74 | Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation. ( Asai, T; Matsui, H; Murakami, H; Murakami, R; Murohara, T; Numaguchi, Y; Okumura, K; Takahashi, R; Tsuzuki, M, 2007) |
| "Recently we showed that the administration of intraperitoneal L-carnitine (CA) has insulin-sensitizing effects in the high fructose-fed Wistar rat, a widely used model of metabolic syndrome." | 3.74 | Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by L-carnitine: a study in the fructose-fed hypertensive rat. ( Anuradha, CV; Palanisamy, N; Rajasekar, P, 2007) |
| "These results identify the carnitine-transporter gene family as candidate modifiers of LVMI in human hypertension." | 3.73 | Haplotype analysis of carnitine transporters and left ventricular mass in human essential hypertension. ( Bianchi, G; Bigatti, G; Modica, R; Stella, A; Stella, P; Tripodi, G, 2005) |
| "Oxidative stress plays an important role in arterial hypertension and propionyl-L-carnitine (PLC) has been found to protect cells from toxic reactive oxygen species." | 3.73 | Antioxidant activity of propionyl-L-carnitine in liver and heart of spontaneously hypertensive rats. ( Gómez-Amores, L; Mate, A; Revilla, E; Santa-María, C; Vázquez, CM, 2006) |
| "The Milan hypertensive strain (MHS) of rats, in addition to having hypertension, is also characterized by a genetic deficiency in calpastatin, the endogenous inhibitor of calpain." | 3.69 | A genetic deficiency in calpastatin and isovalerylcarnitine treatment is associated with enhanced hippocampal long-term potentiation. ( Bianchi, G; Molinari, I; Muller, D; Soldati, L, 1995) |
| "This study was undertaken to demonstrate L-carnitine therapeutical effect in patients with essential hypertension." | 3.69 | L-carnitine adjuvant therapy in essential hypertension. ( Bisi, G; Brodbeck, B; Cantini, F; Digiesi, V; Guarino, G, 1994) |
| " SHR and WKY, diabetic or nondiabetic, were equally sensitive to the induction of ventricular arrhythmias by aconitine infusion." | 3.69 | Cardiovascular and metabolic changes in spontaneously hypertensive rats following streptozotocin administration. ( Battell, M; Dai, S; Lee, S; McNeill, JH, 1994) |
| "Reduced myocardial carnitine concentrations in the explanted heart and elevated plasma levels have been found in patients undergoing heart transplant for end-stage congestive heart failure (CHF)." | 3.68 | Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. ( Fleck, E; Regitz, V; Shug, AL, 1990) |
| "Hypertension is the most prevalent chronic disease and a risk factor for various diseases." | 2.72 | TMA/TMAO in Hypertension: Novel Horizons and Potential Therapies. ( Ding, YJ; Jia, QJ; Li, YY; Lv, SC; Wang, YJ; Zhang, A; Zhang, JP; Zhang, WQ; Zhang, XN; Zhu, YP, 2021) |
| "Carnitine is a natural substance essential for the mitochondrial oxidation of long-chain fatty acids and therefore regulates the energy metabolism of the cells." | 2.66 | [The benefits of L-carnitine therapy in essential arterial hypertension with diabetes mellitus type II]. ( Cantini, F; Digiesi, V; Palchetti, R, 1989) |
| "L-carnitine plays a fundamental biological role in the metabolism of lipids and may positively affect blood pressure by decreasing insulin resistance, although the latter remains less clear." | 2.61 | Effects of L-carnitine supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. ( Askarpour, M; Dehghani Kari Bozorg, A; Ghaedi, E; Hadi, A; Kazemi, M; Sadeghi, O; Sheikhi, A, 2019) |
| "l-carnitine (LC) is a naturally occurring compound that is administered exogenously for treatment of patients that are deficient in carnitine." | 2.46 | The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage. ( Mate, A; Miguel-Carrasco, JL; Vázquez, CM, 2010) |
| "Carnitine is a potent endogenous antioxidant and cellular fatty acid transporter for antioxidative stress and energy production in the cardiovascular system." | 1.62 | Role of carnitine in regulation of blood pressure (MAP/SBP) and gene expression of cardiac hypertrophy markers (α/β-MHC) during insulin-induced hypoglycaemia: Role of oxidative stress. ( Al-Harbi, NO; Alanazi, MM; Alanazi, WA; Alasmari, AF; Alasmari, F; Alhoshani, A; Ali, N; Ansari, MA; Imam, F, 2021) |
| "L-Carnitine transport was measured at different extracellular pH (pHo 5." | 1.40 | Reduced L-carnitine transport in aortic endothelial cells from spontaneously hypertensive rats. ( Arroyo, P; Blanca, AJ; Guzmán-Gutiérrez, E; Leiva, A; Mate, A; Pardo, F; Ruiz-Armenta, MV; Salomón, C; Salsoso, R; Sobrevia, L; Vázquez, CM; Zambrano, S, 2014) |
| "Arterial hypertension is associated with a high production of reactive oxygen species and a decrease in the antioxidant defense systems." | 1.39 | The renoprotective effect of L-carnitine in hypertensive rats is mediated by modulation of oxidative stress-related gene expression. ( Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Revilla, E; Ruiz-Armenta, MV; Santa-María, C; Vázquez, CM; Zambrano, S, 2013) |
| "Cardiac fibrosis is a pathogenic factor in a variety of cardiovascular diseases and is characterized by an abnormal accumulation of extracellular matrix protein that leads to cardiac dysfunction." | 1.39 | L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Vázquez, MJ; Zambrano, S, 2013) |
| "Hypertension is a well established risk factor for the development of cardiovascular diseases and increased mortality." | 1.37 | Administration of L-carnitine and mildronate improves endothelial function and decreases mortality in hypertensive Dahl rats. ( Cirule, H; Dambrova, M; Grinberga, S; Kalvinsh, I; Kuka, J; Liepinsh, E; Svalbe, B; Vilskersts, R, 2011) |
| "Treatment with captopril was also performed in SHR in order to compare the antioxidant and antihypertensive effects of LC and captopril." | 1.36 | Systemic antioxidant properties of L-carnitine in two different models of arterial hypertension. ( Mate, A; Miguel-Carrasco, JL; Monserrat, MT; Vázquez, CM, 2010) |
| "The chronic administration of LC reduces blood pressure and attenuates the inflammatory process associated with arterial hypertension." | 1.35 | The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. ( Aramburu, O; Arias, JL; Mate, A; Miguel-Carrasco, JL; Monserrat, MT; Vázquez, CM, 2008) |
| "L-Carnitine treatment for 6 weeks lowered significantly both the systolic and mean arterial pressure of SHR but its influence on diastolic and pulse pressure was only modest." | 1.30 | The effect of chronic L-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats. ( Dobesová, Z; Drahota, Z; Kunes, J; Rauchová, H; Zicha, J, 1998) |
| "Carnitine metabolism was examined in spontaneously hypertensive rats (SHR)." | 1.27 | Altered carnitine metabolism in spontaneously hypertensive rats. ( Foster, KA; O'Rourke, B; Reibel, DK, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (9.80) | 18.7374 |
| 1990's | 7 (13.73) | 18.2507 |
| 2000's | 12 (23.53) | 29.6817 |
| 2010's | 19 (37.25) | 24.3611 |
| 2020's | 8 (15.69) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, Z | 1 |
| Zhang, N | 1 |
| Song, Y | 3 |
| Liu, L | 4 |
| Li, J | 3 |
| Zhang, Y | 2 |
| Huo, Y | 2 |
| Liu, X | 2 |
| Duan, Y | 1 |
| Wang, B | 4 |
| Zhang, H | 3 |
| Guo, H | 2 |
| Qin, X | 2 |
| Wang, X | 3 |
| Xu, X | 2 |
| Louca, P | 1 |
| Tran, TQB | 1 |
| Toit, CD | 1 |
| Christofidou, P | 1 |
| Spector, TD | 1 |
| Mangino, M | 1 |
| Suhre, K | 1 |
| Padmanabhan, S | 1 |
| Menni, C | 1 |
| Shi, YF | 1 |
| Jiang, YP | 1 |
| Wang, XZ | 1 |
| Sun, PP | 1 |
| Zhu, NJ | 1 |
| Wang, K | 1 |
| Zhang, ZQ | 1 |
| Liu, YY | 1 |
| Huo, J | 1 |
| Wang, XR | 1 |
| Ding, B | 1 |
| Liu, T | 3 |
| Liu, C | 2 |
| Wei, Y | 2 |
| Li, S | 3 |
| Chen, P | 2 |
| Shi, H | 2 |
| Qutob, HMH | 1 |
| Saad, RA | 1 |
| Bali, H | 1 |
| Osailan, A | 1 |
| Jaber, J | 1 |
| Alzahrani, E | 1 |
| Alyami, J | 1 |
| Elsayed, H | 1 |
| Alserihi, R | 1 |
| Shaikhomar, OA | 1 |
| Divya, KM | 1 |
| Savitha, DP | 1 |
| Krishna, GA | 1 |
| Dhanya, TM | 1 |
| Mohanan, PV | 1 |
| Shah, SF | 1 |
| Jafry, AT | 1 |
| Hussain, G | 1 |
| Kazim, AH | 1 |
| Ali, M | 1 |
| Rivani, E | 1 |
| Endraswari, PD | 1 |
| Widodo, ADW | 1 |
| Khalil, MR | 1 |
| Guldberg, R | 1 |
| Nørgård, BM | 1 |
| Uldbjerg, N | 1 |
| Wehberg, S | 1 |
| Fowobaje, KR | 1 |
| Mashood, LO | 1 |
| Ekholuenetale, M | 1 |
| Ibidoja, OJ | 1 |
| Romagnoli, A | 1 |
| D'Agostino, M | 1 |
| Pavoni, E | 1 |
| Ardiccioni, C | 1 |
| Motta, S | 1 |
| Crippa, P | 1 |
| Biagetti, G | 1 |
| Notarstefano, V | 1 |
| Rexha, J | 1 |
| Perta, N | 1 |
| Barocci, S | 1 |
| Costabile, BK | 1 |
| Colasurdo, G | 1 |
| Caucci, S | 1 |
| Mencarelli, D | 1 |
| Turchetti, C | 1 |
| Farina, M | 1 |
| Pierantoni, L | 1 |
| La Teana, A | 1 |
| Al Hadi, R | 1 |
| Cicconardi, F | 1 |
| Chinappi, M | 1 |
| Trucchi, E | 1 |
| Mancia, F | 1 |
| Menzo, S | 1 |
| Morozzo Della Rocca, B | 1 |
| D'Annessa, I | 1 |
| Di Marino, D | 1 |
| Choya, A | 1 |
| de Rivas, B | 1 |
| Gutiérrez-Ortiz, JI | 1 |
| López-Fonseca, R | 1 |
| Xu, S | 1 |
| Cheng, B | 1 |
| Huang, Z | 1 |
| Li, Y | 2 |
| Jiang, L | 1 |
| Guo, W | 1 |
| Xiong, J | 1 |
| Amirazodi, M | 1 |
| Daryanoosh, F | 1 |
| Mehrabi, A | 1 |
| Gaeini, A | 1 |
| Koushkie Jahromi, M | 1 |
| Salesi, M | 1 |
| Zarifkar, AH | 1 |
| Studeny, P | 1 |
| Netukova, M | 1 |
| Nemcokova, M | 1 |
| Klimesova, YM | 1 |
| Krizova, D | 1 |
| Kang, H | 1 |
| Tao, Y | 1 |
| Zhang, Q | 1 |
| Sha, D | 1 |
| Chen, Y | 1 |
| Yao, J | 1 |
| Gao, Y | 1 |
| Liu, J | 1 |
| Ji, L | 1 |
| Shi, P | 1 |
| Shi, C | 1 |
| Wu, YL | 1 |
| Wright, AI | 1 |
| M El-Metwaly, N | 1 |
| A Katouah, H | 1 |
| El-Desouky, MG | 1 |
| El-Bindary, AA | 1 |
| El-Bindary, MA | 1 |
| Kostakis, ID | 1 |
| Raptis, DA | 1 |
| Davidson, BR | 1 |
| Iype, S | 1 |
| Nasralla, D | 1 |
| Imber, C | 1 |
| Sharma, D | 1 |
| Pissanou, T | 1 |
| Pollok, JM | 1 |
| Hughes, AM | 1 |
| Sanderson, E | 1 |
| Morris, T | 1 |
| Ayorech, Z | 1 |
| Tesli, M | 1 |
| Ask, H | 1 |
| Reichborn-Kjennerud, T | 1 |
| Andreassen, OA | 1 |
| Magnus, P | 1 |
| Helgeland, Ø | 1 |
| Johansson, S | 1 |
| Njølstad, P | 1 |
| Davey Smith, G | 1 |
| Havdahl, A | 1 |
| Howe, LD | 1 |
| Davies, NM | 1 |
| Amrillah, T | 1 |
| Prasetio, A | 1 |
| Supandi, AR | 1 |
| Sidiq, DH | 1 |
| Putra, FS | 1 |
| Nugroho, MA | 1 |
| Salsabilla, Z | 1 |
| Azmi, R | 1 |
| Grammatikopoulos, P | 1 |
| Bouloumis, T | 1 |
| Steinhauer, S | 1 |
| Mironov, VS | 2 |
| Bazhenova, TA | 2 |
| Manakin, YV | 2 |
| Yagubskii, EB | 2 |
| Yakushev, IA | 1 |
| Gilmutdinov, IF | 1 |
| Simonov, SV | 1 |
| Lan, K | 1 |
| Yang, H | 1 |
| Zheng, J | 1 |
| Hu, H | 1 |
| Zhu, T | 1 |
| Zou, X | 1 |
| Hu, B | 1 |
| Liu, H | 1 |
| Olokede, O | 1 |
| Wu, H | 1 |
| Holtzapple, M | 1 |
| Gungor, O | 1 |
| Kose, M | 1 |
| Ghaemi, R | 1 |
| Acker, M | 1 |
| Stosic, A | 1 |
| Jacobs, R | 1 |
| Selvaganapathy, PR | 1 |
| Ludwig, N | 1 |
| Yerneni, SS | 1 |
| Azambuja, JH | 1 |
| Pietrowska, M | 1 |
| Widłak, P | 1 |
| Hinck, CS | 1 |
| Głuszko, A | 1 |
| Szczepański, MJ | 1 |
| Kärmer, T | 1 |
| Kallinger, I | 1 |
| Schulz, D | 1 |
| Bauer, RJ | 1 |
| Spanier, G | 1 |
| Spoerl, S | 1 |
| Meier, JK | 1 |
| Ettl, T | 1 |
| Razzo, BM | 1 |
| Reichert, TE | 1 |
| Hinck, AP | 1 |
| Whiteside, TL | 1 |
| Wei, ZL | 1 |
| Juan, W | 1 |
| Tong, D | 1 |
| Juan, LX | 1 |
| Sa, LY | 1 |
| Jie, HFM | 1 |
| Xiao, G | 1 |
| Xiang, LG | 1 |
| Jie, HM | 1 |
| Xu, C | 1 |
| Yu, DN | 1 |
| Yao, ZX | 1 |
| Bigdeli, F | 1 |
| Gao, XM | 1 |
| Cheng, X | 1 |
| Li, JZ | 1 |
| Zhang, JW | 1 |
| Wang, W | 2 |
| Guan, ZJ | 1 |
| Bu, Y | 1 |
| Liu, KG | 1 |
| Morsali, A | 1 |
| Das, R | 1 |
| Paul, R | 1 |
| Parui, A | 1 |
| Shrotri, A | 1 |
| Atzori, C | 1 |
| Lomachenko, KA | 1 |
| Singh, AK | 1 |
| Mondal, J | 1 |
| Peter, SC | 1 |
| Florimbio, AR | 1 |
| Coughlin, LN | 1 |
| Bauermeister, JA | 1 |
| Young, SD | 1 |
| Zimmerman, MA | 1 |
| Walton, MA | 1 |
| Bonar, EE | 1 |
| Demir, D | 1 |
| Balci, AB | 1 |
| Kahraman, N | 1 |
| Sunbul, SA | 1 |
| Gucu, A | 1 |
| Seker, IB | 1 |
| Badem, S | 1 |
| Yuksel, A | 1 |
| Ozyazicioglu, AF | 1 |
| Goncu, MT | 1 |
| Zhou, H | 1 |
| Deng, Z | 1 |
| Luo, L | 1 |
| Ong, SP | 1 |
| Wang, C | 1 |
| Xin, H | 1 |
| Whittingham, MS | 1 |
| Zhou, G | 1 |
| Maemura, R | 1 |
| Wakamatsu, M | 1 |
| Matsumoto, K | 1 |
| Sakaguchi, H | 1 |
| Yoshida, N | 1 |
| Hama, A | 1 |
| Yoshida, T | 1 |
| Miwata, S | 1 |
| Kitazawa, H | 1 |
| Narita, K | 1 |
| Kataoka, S | 1 |
| Ichikawa, D | 1 |
| Hamada, M | 1 |
| Taniguchi, R | 1 |
| Suzuki, K | 1 |
| Kawashima, N | 1 |
| Nishikawa, E | 1 |
| Narita, A | 1 |
| Okuno, Y | 1 |
| Nishio, N | 1 |
| Kato, K | 1 |
| Kojima, S | 1 |
| Morita, K | 1 |
| Muramatsu, H | 1 |
| Takahashi, Y | 1 |
| Yirgu, A | 1 |
| Mekonnen, Y | 1 |
| Eyado, A | 1 |
| Staropoli, A | 1 |
| Vinale, F | 1 |
| Zac, J | 1 |
| Zac, S | 1 |
| Pérez-Padilla, R | 1 |
| Remigio-Luna, A | 1 |
| Guzmán-Boulloud, N | 1 |
| Gochicoa-Rangel, L | 1 |
| Guzmán-Valderrábano, C | 1 |
| Thirión-Romero, I | 1 |
| Statsenko, ME | 2 |
| Turkina, SV | 2 |
| Barantsevich, ER | 1 |
| Karakulova, YV | 1 |
| Baranova, NS | 1 |
| Morzhukhina, MV | 1 |
| Wang, Q | 1 |
| Gu, Y | 1 |
| Chen, C | 1 |
| Qiao, L | 1 |
| Pan, F | 1 |
| Song, C | 1 |
| Canetto, SS | 1 |
| Entilli, L | 1 |
| Cerbo, I | 1 |
| Cipolletta, S | 1 |
| Wu, Y | 2 |
| Zhu, P | 1 |
| Jiang, Y | 1 |
| Zhang, X | 1 |
| Wang, Z | 1 |
| Xie, B | 1 |
| Song, T | 1 |
| Zhang, F | 1 |
| Luo, A | 1 |
| Xiong, X | 1 |
| Han, J | 1 |
| Peng, X | 1 |
| Li, M | 1 |
| Huang, L | 1 |
| Chen, Q | 1 |
| Fang, W | 1 |
| Hou, Y | 1 |
| Zhu, Y | 1 |
| Ye, J | 1 |
| Islam, MR | 1 |
| Sanderson, P | 1 |
| Johansen, MP | 1 |
| Payne, TE | 1 |
| Naidu, R | 1 |
| Cao, J | 1 |
| Yang, J | 1 |
| Niu, X | 1 |
| Zhai, Y | 1 |
| Qiang, C | 1 |
| Niu, Y | 1 |
| Li, Z | 1 |
| Dong, N | 1 |
| Wen, B | 1 |
| Ouyang, Z | 1 |
| Zhao, M | 1 |
| Zhao, J | 1 |
| Morici, P | 1 |
| Rizzato, C | 1 |
| Ghelardi, E | 1 |
| Rossolini, GM | 1 |
| Lupetti, A | 1 |
| Gözüküçük, R | 1 |
| Cakiroglu, B | 1 |
| He, X | 1 |
| Li, R | 1 |
| Zhao, D | 1 |
| Zhang, L | 1 |
| Ji, X | 1 |
| Fan, X | 1 |
| Chen, J | 1 |
| Wang, Y | 2 |
| Luo, Y | 1 |
| Zheng, D | 1 |
| Xie, L | 2 |
| Sun, S | 1 |
| Cai, Z | 1 |
| Liu, Q | 1 |
| Ma, K | 1 |
| Sun, X | 1 |
| Drinkwater, JJ | 1 |
| Davis, TME | 1 |
| Turner, AW | 1 |
| Davis, WA | 1 |
| Suzuki, Y | 1 |
| Mizuta, Y | 1 |
| Mikagi, A | 1 |
| Misawa-Suzuki, T | 1 |
| Tsuchido, Y | 1 |
| Sugaya, T | 1 |
| Hashimoto, T | 1 |
| Ema, K | 1 |
| Hayashita, T | 1 |
| Askarpour, M | 1 |
| Hadi, A | 1 |
| Dehghani Kari Bozorg, A | 1 |
| Sadeghi, O | 1 |
| Sheikhi, A | 1 |
| Kazemi, M | 1 |
| Ghaedi, E | 1 |
| Alanazi, WA | 1 |
| Al-Harbi, NO | 1 |
| Imam, F | 1 |
| Ansari, MA | 1 |
| Alhoshani, A | 1 |
| Alasmari, AF | 1 |
| Alasmari, F | 1 |
| Alanazi, MM | 1 |
| Ali, N | 1 |
| Zhang, WQ | 1 |
| Wang, YJ | 1 |
| Zhang, A | 1 |
| Ding, YJ | 1 |
| Zhang, XN | 1 |
| Jia, QJ | 1 |
| Zhu, YP | 1 |
| Li, YY | 1 |
| Lv, SC | 1 |
| Zhang, JP | 1 |
| Skoromets, AA | 1 |
| Kotov, SV | 1 |
| Voronkov, PB | 1 |
| Popova, VV | 1 |
| Zubkova, TG | 1 |
| Kiselev, AV | 1 |
| Blanca, AJ | 5 |
| Ruiz-Armenta, MV | 5 |
| Zambrano, S | 5 |
| Miguel-Carrasco, JL | 8 |
| González-Roncero, FM | 1 |
| Fortuño, A | 1 |
| Revilla, E | 4 |
| Mate, A | 10 |
| Vázquez, CM | 12 |
| Elmariah, S | 1 |
| Farrell, LA | 1 |
| Furman, D | 1 |
| Lindman, BR | 1 |
| Shi, X | 1 |
| Morningstar, JE | 1 |
| Rhee, EP | 1 |
| Gerszten, RE | 1 |
| Nie, J | 1 |
| Zhao, BX | 1 |
| Qiu, B | 1 |
| Zhu, F | 1 |
| Li, GF | 1 |
| He, M | 1 |
| Liu, S | 1 |
| Cai, Y | 1 |
| Hou, FF | 1 |
| Khan, HA | 1 |
| Alhomida, AS | 1 |
| Zahradka, P | 1 |
| Wright, B | 1 |
| Weighell, W | 1 |
| Blewett, H | 1 |
| Baldwin, A | 1 |
| O, K | 1 |
| Guzman, RP | 1 |
| Taylor, CG | 1 |
| Arévalo, M | 2 |
| Kępka, A | 1 |
| Kuroczycka-Saniutycz, E | 1 |
| Chojnowska, S | 1 |
| Fiłonowicz, R | 1 |
| Korzeniecka-Kozerska, A | 1 |
| Wasilewska, A | 2 |
| Salsoso, R | 1 |
| Guzmán-Gutiérrez, E | 1 |
| Arroyo, P | 1 |
| Salomón, C | 1 |
| Pardo, F | 1 |
| Leiva, A | 1 |
| Sobrevia, L | 1 |
| Khukhlina, OS | 1 |
| Mandryk, OIe | 1 |
| Drozd, VIu | 1 |
| Haĭdychuk, VS | 1 |
| Kosar, LIu | 1 |
| Winter, S | 1 |
| Buist, NR | 1 |
| Longo, N | 1 |
| Armenian, SH | 1 |
| Lopaschuk, G | 1 |
| Monserrat, MT | 2 |
| Arias, JL | 1 |
| Aramburu, O | 1 |
| Davis, PA | 1 |
| Mormino, P | 1 |
| Savica, V | 1 |
| Calò, LA | 1 |
| Muniyappa, R | 1 |
| O'Brien, D | 1 |
| Chunduri, P | 1 |
| Iyer, A | 1 |
| Brown, L | 1 |
| Vilskersts, R | 1 |
| Kuka, J | 1 |
| Svalbe, B | 1 |
| Cirule, H | 1 |
| Liepinsh, E | 1 |
| Grinberga, S | 1 |
| Kalvinsh, I | 1 |
| Dambrova, M | 1 |
| Mels, CM | 1 |
| Schutte, AE | 1 |
| Erasmus, E | 1 |
| Huisman, HW | 1 |
| Schutte, R | 1 |
| Fourie, CM | 1 |
| Kruger, R | 1 |
| Van Rooyen, JM | 1 |
| Smith, W | 1 |
| Malan, NT | 1 |
| Malan, L | 1 |
| Santa-María, C | 3 |
| Vázquez, MJ | 1 |
| Herrera, MD | 4 |
| Bueno, R | 3 |
| De Sotomayor, MA | 2 |
| Pérez-Guerrero, C | 3 |
| Marhuenda, E | 2 |
| Tripodi, G | 1 |
| Modica, R | 1 |
| Stella, A | 1 |
| Bigatti, G | 1 |
| Bianchi, G | 3 |
| Stella, P | 1 |
| Alvarez de Sotomayor, M | 2 |
| Gomez-Amores, L | 3 |
| Jiménez, L | 1 |
| Jos, A | 1 |
| Cameán, AM | 1 |
| Mingorance, C | 1 |
| Rodriguez-Rodriguez, R | 1 |
| Takahashi, R | 1 |
| Asai, T | 1 |
| Murakami, H | 1 |
| Murakami, R | 1 |
| Tsuzuki, M | 1 |
| Numaguchi, Y | 1 |
| Matsui, H | 1 |
| Murohara, T | 1 |
| Okumura, K | 1 |
| Rajasekar, P | 1 |
| Palanisamy, N | 1 |
| Anuradha, CV | 1 |
| Bocchini, G | 1 |
| Bonanno, G | 1 |
| Muller, D | 1 |
| Molinari, I | 1 |
| Soldati, L | 1 |
| Digiesi, V | 2 |
| Cantini, F | 2 |
| Bisi, G | 1 |
| Guarino, G | 1 |
| Brodbeck, B | 1 |
| Dai, S | 1 |
| Lee, S | 1 |
| Battell, M | 1 |
| McNeill, JH | 1 |
| Micheletti, R | 1 |
| Giacalone, G | 1 |
| Canepari, M | 1 |
| Salardi, S | 1 |
| Reggiani, C | 1 |
| Rauchová, H | 1 |
| Dobesová, Z | 1 |
| Drahota, Z | 1 |
| Zicha, J | 1 |
| Kunes, J | 1 |
| Sloan, RS | 1 |
| Kastan, B | 1 |
| Rice, SI | 1 |
| Sallee, CW | 1 |
| Yuenger, NJ | 1 |
| Smith, B | 1 |
| Ward, RA | 1 |
| Brier, ME | 1 |
| Golper, TA | 1 |
| Nakamura, T | 1 |
| Sugihara, H | 1 |
| Kinoshita, N | 1 |
| Yoneyama, S | 1 |
| Azuma, A | 1 |
| Nakagawa, M | 1 |
| Williams, ES | 1 |
| Luft, FC | 1 |
| Regitz, V | 1 |
| Shug, AL | 1 |
| Fleck, E | 1 |
| Palchetti, R | 1 |
| Hamlin, RL | 1 |
| Buffington, CA | 1 |
| Foster, KA | 1 |
| O'Rourke, B | 1 |
| Reibel, DK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Acetyl L-Carnitine in Patients With Covid-19 Pneumonia[NCT04623619] | 100 participants (Anticipated) | Interventional | 2020-12-15 | Not yet recruiting | |||
| Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.[NCT00794885] | Phase 4 | 20,702 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Blinded, Randomized, Controlled Study to Examine the Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.[NCT02342340] | 8 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for carnitine and Hypertension
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Effects of L-carnitine supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Carnitine; Dietary Suppleme | 2019 |
TMA/TMAO in Hypertension: Novel Horizons and Potential Therapies.
Topics: Animals; Carnitine; Choline; Gastrointestinal Microbiome; Glucose; Humans; Hypertension; Inflammatio | 2021 |
The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage.
Topics: Animals; Antihypertensive Agents; Cardiotonic Agents; Cardiovascular Diseases; Carnitine; Drug Deliv | 2010 |
Nutrition and the heart.
Topics: Animals; Cachexia; Carnitine; Cat Diseases; Cats; Diet; Dog Diseases; Dogs; Heart Diseases; Heart Fa | 1989 |
4 trials available for carnitine and Hypertension
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Topics: Acetylcarnitine; Aged; Cardiovascular Diseases; Carnitine; Cerebrovascular Disorders; Chronic Diseas | 2021 |
Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carnitine; Diabetes Complications; Female; Hea | 1998 |
[The benefits of L-carnitine therapy in essential arterial hypertension with diabetes mellitus type II].
Topics: Aged; Arrhythmias, Cardiac; Blood Pressure; Carnitine; Clinical Trials as Topic; Diabetes Mellitus, | 1989 |
43 other studies available for carnitine and Hypertension
| Article | Year |
|---|---|
Serum L-Carnitine Levels Are Associated With First Stroke in Chinese Adults With Hypertension.
Topics: Adult; Carnitine; Case-Control Studies; China; Folic Acid; Genotype; Humans; Hypertension; Methylene | 2022 |
Machine learning integration of multimodal data identifies key features of blood pressure regulation.
Topics: alpha-Linolenic Acid; Biomarkers; Blood Pressure; Carnitine; Chlorides; Creatinine; Humans; Hyperten | 2022 |
Chiral Luminescent Sensor Eu-BTB@d-Carnitine Applied in the Highly Effective Ratiometric Sensing of Curing Drugs and Biomarkers for Diabetes and Hypertension.
Topics: Biomarkers; Carnitine; Clonidine; Diabetes Mellitus; Europium; Humans; Hypertension; Insulins; Metal | 2022 |
The Association of Serum L-Carnitine Concentrations with the Risk of Cancer in Chinese Adults with Hypertension.
Topics: Adult; Carnitine; Case-Control Studies; East Asian People; Female; Humans; Hypertension; Male; Methy | 2022 |
The Association of Serum L-Carnitine Concentrations with the Risk of Cancer in Chinese Adults with Hypertension.
Topics: Adult; Carnitine; Case-Control Studies; East Asian People; Female; Humans; Hypertension; Male; Methy | 2022 |
The Association of Serum L-Carnitine Concentrations with the Risk of Cancer in Chinese Adults with Hypertension.
Topics: Adult; Carnitine; Case-Control Studies; East Asian People; Female; Humans; Hypertension; Male; Methy | 2022 |
The Association of Serum L-Carnitine Concentrations with the Risk of Cancer in Chinese Adults with Hypertension.
Topics: Adult; Carnitine; Case-Control Studies; East Asian People; Female; Humans; Hypertension; Male; Methy | 2022 |
Role of carnitine in regulation of blood pressure (MAP/SBP) and gene expression of cardiac hypertrophy markers (α/β-MHC) during insulin-induced hypoglycaemia: Role of oxidative stress.
Topics: Animals; Blood Pressure; Cardiomyopathies; Carnitine; Hyperammonemia; Hypertension; Muscular Disease | 2021 |
l-Carnitine ameliorates the oxidative stress response to angiotensin II by modulating NADPH oxidase through a reduction in protein kinase c activity and NF-κB translocation to the nucleus.
Topics: Angiotensin II; Animals; Carnitine; Hypertension; NADPH Oxidases; NF-kappa B; Oxidative Stress; Prot | 2017 |
Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.
Topics: Aged, 80 and over; Aortic Valve Stenosis; Biomarkers; Carnitine; Choline; Diabetes Complications; Fe | 2018 |
Serum Trimethylamine N-Oxide Concentration Is Positively Associated With First Stroke in Hypertensive Patients.
Topics: Aged; Carnitine; Case-Control Studies; China; Choline; Female; Folic Acid; Gastrointestinal Microbio | 2018 |
Single nucleotide polymorphism in CPT1B and CPT2 genes and its association with blood carnitine levels in acute myocardial infarction patients.
Topics: Adult; Aged; Aged, 80 and over; Carnitine; Carnitine O-Palmitoyltransferase; Case-Control Studies; D | 2013 |
Daily non-soy legume consumption reverses vascular impairment due to peripheral artery disease.
Topics: Aged; Aged, 80 and over; Ankle Brachial Index; Atherosclerosis; Biomarkers; Carnitine; Carotid Steno | 2013 |
L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ.
Topics: Animals; Carnitine; Cells, Cultured; Collagen; Connective Tissue Growth Factor; Cytoprotection; Dise | 2014 |
Urine L-carnitine excretion in hypertensive adolescents.
Topics: Adolescent; Carnitine; Child; Cohort Studies; Creatinine; Female; Humans; Hypertension; Kidney; Male | 2015 |
Reduced L-carnitine transport in aortic endothelial cells from spontaneously hypertensive rats.
Topics: Animals; Aorta; Biological Transport; Blood Pressure; Calcitonin Gene-Related Peptide; Carnitine; Ca | 2014 |
[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II].
Topics: Adenine; Anticholesteremic Agents; Azetidines; Carnitine; Drug Combinations; Endothelium, Vascular; | 2014 |
Round Table Discussion.
Topics: Adolescent; Autistic Disorder; Biomedical Research; Cardiomyopathies; Carnitine; Child; Congresses a | 2016 |
The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension.
Topics: Animals; Biomarkers; Blood Pressure; Body Weight; Cardiotonic Agents; Carnitine; Disease Models, Ani | 2008 |
L-carnitine, inflammation and hypertension.
Topics: Carnitine; Heme Oxygenase-1; Humans; Hypertension; Inflammation; NG-Nitroarginine Methyl Ester | 2009 |
Oral carnitine therapy and insulin resistance.
Topics: Administration, Oral; Carnitine; Female; Humans; Hypertension; Insulin Resistance; Male; Prognosis; | 2010 |
L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Carnitine; Desoxycorticosterone; Endothelium, Vascular; Hy | 2010 |
Systemic antioxidant properties of L-carnitine in two different models of arterial hypertension.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Captopril; Carnitine; Glutathione; G | 2010 |
Administration of L-carnitine and mildronate improves endothelial function and decreases mortality in hypertensive Dahl rats.
Topics: Animals; Cardiovascular Agents; Carnitine; Endothelium, Vascular; Hypertension; Male; Methylhydrazin | 2011 |
L-carnitine and long-chain acylcarnitines are positively correlated with ambulatory blood pressure in humans: the SABPA study.
Topics: Adult; Black People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carnitine; Cross-Section | 2013 |
The renoprotective effect of L-carnitine in hypertensive rats is mediated by modulation of oxidative stress-related gene expression.
Topics: Animals; Antioxidants; Carnitine; Down-Regulation; Gene Expression Regulation; Glutathione Peroxidas | 2013 |
L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression.
Topics: Animals; Antihypertensive Agents; Carnitine; Collagen Type I; Collagen Type II; Connective Tissue Gr | 2013 |
Endothelium-dependent vasorelaxation induced by L-carnitine in isolated aorta from normotensive and hypertensive rats.
Topics: Animals; Aorta, Thoracic; Carnitine; Dioxanes; Endothelium, Vascular; Enzyme Inhibitors; Hypertensio | 2002 |
Haplotype analysis of carnitine transporters and left ventricular mass in human essential hypertension.
Topics: Adult; Aged; Carnitine; Carnitine O-Palmitoyltransferase; Female; Gene Frequency; Genotype; Haplotyp | 2005 |
L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products.
Topics: Administration, Oral; Animals; Antioxidants; Aorta, Thoracic; Blood Pressure; Body Weight; Carnitine | 2005 |
Antioxidant activity of propionyl-L-carnitine in liver and heart of spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Blood Pressure; Carnitine; Catalase; Enzymes; Glutathione Peroxidase; Glutath | 2006 |
L-carnitine attenuates oxidative stress in hypertensive rats.
Topics: Animals; Blood Pressure; Carnitine; Glutathione; Glutathione Disulfide; Glutathione Reductase; Hyper | 2007 |
Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR.
Topics: Animals; Biological Factors; Blood Pressure; Carbachol; Carnitine; Cyclooxygenase Inhibitors; Endoth | 2007 |
l-carnitine and its propionate: improvement of endothelial function in SHR through superoxide dismutase-dependent mechanisms.
Topics: Animals; Antioxidants; Blood Pressure; Carnitine; Endothelium, Vascular; Hypertension; Male; NG-Nitr | 2007 |
Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation.
Topics: Adenosine Triphosphate; Animals; Aorta; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Car | 2007 |
Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by L-carnitine: a study in the fructose-fed hypertensive rat.
Topics: Animals; Blood Pressure; Carnitine; Disease Models, Animal; Hypertension; Male; Metabolic Syndrome; | 2007 |
[Effect of several drugs on hypertension and cerebral monoamine oxidase activity in old rats exposed to environmental stress].
Topics: Animals; Brain; Carnitine; Food, Formulated; Hemodynamics; Humans; Hypertension; Monoamine Oxidase; | 1981 |
A genetic deficiency in calpastatin and isovalerylcarnitine treatment is associated with enhanced hippocampal long-term potentiation.
Topics: Animals; Calcium-Binding Proteins; Calpain; Carnitine; Hippocampus; Hypertension; Long-Term Potentia | 1995 |
L-carnitine adjuvant therapy in essential hypertension.
Topics: Adult; Aged; Carnitine; Chemotherapy, Adjuvant; Cholesterol; Female; Heart Rate; Humans; Hypertensio | 1994 |
Cardiovascular and metabolic changes in spontaneously hypertensive rats following streptozotocin administration.
Topics: Aconitine; Animals; Arrhythmias, Cardiac; Blood Glucose; Blood Pressure; Carnitine; Diabetes Mellitu | 1994 |
Propionyl-L-carnitine prevents myocardial mechanical alterations due to pressure overload in rats.
Topics: Animals; Aorta; Cardiomegaly; Cardiotonic Agents; Carnitine; Constriction, Pathologic; Heart; Heart | 1994 |
The effect of chronic L-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Carnitine; Heart Rate; Hypertension; Lipids; Male; Organ Size; | 1998 |
Can serum carnitine levels distinguish hypertrophic cardiomyopathy from hypertensive hearts?
Topics: Adult; Aged; Analysis of Variance; Cardiomyopathy, Hypertrophic; Carnitine; Diagnosis, Differential; | 2000 |
The effect of chronic uremia on fatty acid metabolism in the heart.
Topics: Animals; Blood Pressure; Body Weight; Carnitine; Chronic Disease; Creatinine; Fatty Acids; Hematocri | 1978 |
Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases.
Topics: Adult; Biopsy; Cardiomyopathy, Dilated; Carnitine; Coronary Disease; Endocardium; Energy Metabolism; | 1990 |
Altered carnitine metabolism in spontaneously hypertensive rats.
Topics: Animals; Body Weight; Cardiomegaly; Carnitine; Hypertension; Liver; Male; Muscles; Myocardium; Organ | 1985 |